-
Mashup Score: 0AACE 2024 Annual Meeting - 10 hour(s) ago
Mark your calendars! AACE Annual Meeting 2024 will be held in New Orleans, Louisiana on May 9-11. Registration coming soon.
Source: pro.aace.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 46Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia - 2 day(s) ago
Hyperglycemia in patients with type 2 diabetes mellitus is frequently encountered in the hospital setting. The recent guidelines for the management of inpatient hyperglycemia have included the use of dipeptidyl peptidase 4 inhibitors as an alternative to standard insulin therapy in select patients. This raises the question of the inpatient use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), which have gained increasing popularity in the outpatient setting because of beneficial cardiovascular and renal outcomes.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 4Optimizing Insulin Therapy in Type 2 Diabetes: Strategies for Individualized Care - Monograph - 2 day(s) ago
The goal of this course is to
Source: pro.aace.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 8
Sodium-glucose-cotransporter 2 (SGLT-2) inhibitors are widely used for diabetes management especially because their effects go beyond glucose control. More recently, their indications and usage have expanded to heart failure (HF) and renal dysfunction therapy in patients both with and without diabetes. Beneficial effects, especially for HF readmission, accrue very early in their treatment trajectory, and this has promoted their use in the hospital setting. Data on their safety and efficacy for inpatient use are accumulating but have lagged behind the outpatient data for their use.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1AACE 2024 Annual Meeting - 3 day(s) ago
Mark your calendars! AACE Annual Meeting 2024 will be held in New Orleans, Louisiana on May 9-11. Registration coming soon.
Source: pro.aace.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1AACE 2024 Annual Meeting - 5 day(s) ago
Mark your calendars! AACE Annual Meeting 2024 will be held in New Orleans, Louisiana on May 9-11. Registration coming soon.
Source: pro.aace.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 0
Unlock the Power to Transform Lives: Discover the keys to clinically meaningful weight loss thresholds and revolutionize your approach to tackling obesity complications! In our comprehensive program, esteemed faculty members will delve into cutting-edge presentations, including the use of Anti-Obesity Medications (AOM) for significant weight loss, the resolution of obesity complications, and the integration of combination therapies with SGLT-2, GLP-1, and other groundbreaking therapeutics. Gain Knowledge That Transforms Practice!
Source: pro.aace.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 8
Sodium-glucose-cotransporter 2 (SGLT-2) inhibitors are widely used for diabetes management especially because their effects go beyond glucose control. More recently, their indications and usage have expanded to heart failure (HF) and renal dysfunction therapy in patients both with and without diabetes. Beneficial effects, especially for HF readmission, accrue very early in their treatment trajectory, and this has promoted their use in the hospital setting. Data on their safety and efficacy for inpatient use are accumulating but have lagged behind the outpatient data for their use.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 45Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia - 6 day(s) ago
Hyperglycemia in patients with type 2 diabetes mellitus is frequently encountered in the hospital setting. The recent guidelines for the management of inpatient hyperglycemia have included the use of dipeptidyl peptidase 4 inhibitors as an alternative to standard insulin therapy in select patients. This raises the question of the inpatient use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), which have gained increasing popularity in the outpatient setting because of beneficial cardiovascular and renal outcomes.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 4Episode 45: Hypoglycemia Care – Putting The AACE Diabetes Clinical Guideline into Practice - 6 day(s) ago
Clinical experts David Lieb, MD, FACE, Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, and Vin Tangpricha, MD, PhD, FACE, discuss the 2022 AACE diabetes guideline updates and address the issue, “How Should Hypoglycemia Be Managed?” Support for this podcast is provided by Xeris Pharmaceuticals, Inc.
Source: pro.aace.comCategories: General Medicine News, EndocrinologyTweet
#AACE2024 Annual Meeting Call for Abstracts Have your work reviewed by experts in the field of endocrinology and showcased at our Annual Meeting in May! Abstract submissions are being accepted through Friday, Dec. 1, 2023, at 11:59 pm EDT. https://t.co/KKbQaOkpq7 #endotwitter